New
HealthMore in Health →
Roche keeps the faith in giredestrant after a setback in first-line breast cancer
Roche says its investigational breast cancer pill giredestrant could still become a major product, with CEO Thomas Schinecker arguing it may one day outsell Herceptin despite an earlier first-line trial failure.
Key Takeaways
- Roche says it still has high sales expectations for investigational breast cancer pill giredestrant.
- CEO Thomas Schinecker said the drug could outsell Herceptin.
DE
DT Editorial AI··via endpoints.news